Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Ya-Ning Chan, Daniel R. Richardson, Courtney Berry, Stephanie Betancur, Hayden Michael Dumaw, Todd Schwartz, Mackenzi Pergolotti, Susan Coppola, Christopher Jensen, Matthew C. Foster, Ashley L. Bryant

Blood (2022) 140 (Supplement 1): 9074–9075.

https://doi.org/10.1182/blood-2022-166419

Published: 2022

Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 9070–9073.

https://doi.org/10.1182/blood-2022-166715

Published: 2022

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

https://doi.org/10.1182/blood-2022-167316

Published: 2022

Journal Articles

Phase II Study of Tagraxofusp in Newly Diagnosed Secondary Acute Myeloid Leukemia (S-AML) after Previous Exposure to Hypomethylating Agents (TAGALONG Study)

Steven D. Green, Brian Parkin, Catherine Lai, Ivana Gojo, Matthew C. Foster, Joshua F. Zeidner

Blood (2022) 140 (Supplement 1): 11749–11750.

https://doi.org/10.1182/blood-2022-170738

Published: 2022

Journal Articles

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie S. Grover, Paul M. Armistead, James M. Coghill, Jr., Katarzyna Joanna Jamieson, Robert Hagan, J. Kaitlin Morrison, Faith Brianne Buchanan, Catherine Joyce Arago Cheng, Anastasia Ivanova, Tammy Cavallo, John West, Megan Gonzalez, Jonathan S. Serody, Gianpietro Dotti

Blood (2022) 140 (Supplement 1): 7437–7438.

https://doi.org/10.1182/blood-2022-165558

Published: 2022

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amanda F. Cashen, Hongtao Liu, Monzr M. Al Malki, Joshua F. Zeidner, Matthew C. Foster, Angela Pannunzio, Brett Ramsey, Jan Baughman, John Muth, Ouiam Bakkacha, Eileen McNulty, Kenneth Jacobs, Jan K Davidson-Moncada, Andrew H Wei

Blood (2022) 140 (Supplement 1): 12740–12741.

https://doi.org/10.1182/blood-2022-158634

Published: 2022

Journal Articles

Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Antonia V. Bennett, Xianming Tan, Matthew C. Foster, Daniel R. Richardson, Ashley L. Bryant, William A. Wood, Jr., Ashley O. Yocum, Alice S. Mims, Uma Borate, Amy Burd

Blood (2022) 140 (Supplement 1): 3367–3368.

https://doi.org/10.1182/blood-2022-160426

Published: 2022

Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 875.

https://doi.org/10.1182/blood-2021-149115

Published: 2021

Journal Articles

Time Spent at Home Among Older Adults with AML Treated with Hypomethylating Agents and Venetoclax

Christopher E. Jensen, Hillary M. Heiling, Konan E. Beke, Allison M. Deal, Ashley Leak Bryant, Lorinda Adaire Coombs, Matthew C. Foster, Daniel R. Richardson

Blood (2021) 138 (Supplement 1): 281.

https://doi.org/10.1182/blood-2021-144818

Published: 2021

Journal Articles

Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia

Steven M. Johnson, Lori Ramkissoon, James Haberberger, Naomi L Ferguson, Jonathan Galeotti, Daniel R. Richardson, Matthew C. Foster, Jeffrey Ross, Shakti H. Ramkissoon, Joshua F. Zeidner, Daniel Duncan, Nathan Montgomery

Blood (2021) 138 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2021-151796

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2021-151234

Published: 2021

Journal Articles

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Lori Muffly, Jun Yin, Sawyer Jacobson, Anjali Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Frederick R. Appelbaum, Richard A. Larson, Theresa Keegan, Wendy Stock

Blood (2021) 138 (Supplement 1): 337.

https://doi.org/10.1182/blood-2021-148804

Published: 2021

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood (2021) 137 (6): 751–762.

https://doi.org/10.1182/blood.2020007732

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134921

Published: 2020

Journal Articles

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Geoffrey L Uy, MD, Michael P. Rettig, PhD, Stephanie Christ, MS, Ibrahim Aldoss, MD, Michael T. Byrne, DO, Harry P. Erba, MD PhD, Martha L. Arellano, MD, Matthew C Foster, MD, John E. Godwin, MD, Farhad Ravandi, MBBS, Peter H. Sayre, MDPhD, Anjali S Advani, MD, Matthew J. Wieduwilt, MD PhD, Ashkan Emadi, MD, PhD, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Martin Wermke, Norbert Vey, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Antonio Curti, MDPhD, Geert Huls, MD PhD, Max S. Topp, MD, Mojca Jongen-Lavrencic, MD PhD, John Muth, MS, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MDPhDMS, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-134612

Published: 2020

Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-143265

Published: 2020

NARROW

Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Phase II Study of Tagraxofusp in Newly Diagnosed Secondary Acute Myeloid Leukemia (S-AML) after Previous Exposure to Hypomethylating Agents (TAGALONG Study)

Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Time Spent at Home Among Older Adults with AML Treated with Hypomethylating Agents and Venetoclax

Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only